
    
      The study is an open-label, controlled, randomized Phase II clinical trial. The protocol has
      been approved by the Ethics Committee of Beijing Cancer Hospital.

      The primary endpoint is the 3-year progression-free survival (PFS) rate. The secondary
      endpoints are the overall survival, surgical morbidity and mortality.
    
  